Moderna’s race to the vaccine

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the big business and financial stories of the moment with reporting from Financial Times journalists around the world. Hosted by Aimee Keane and produced by Oluwakemi Aladesuyi.

The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.

The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.

Review clips: Yahoo Finance, CNBC

See acast.com/privacy for privacy and opt-out information.

Transcripts are not currently available for all podcasts, view our accessibility guide.

Get alerts on Behind the Money when a new story is published

Reuse this content Comments

Comments have not been enabled for this article.

Moderna’s race to the vaccine

Promoted Content

Follow the topics in this podcast